The 28 European Union member governments have concluded next steps for addressing antimicrobial resistance, with a strong emphasis on reducing use of antibiotics in animals, but also including a call for new business models.
There does not appear to be a mention of price, intellectual property rights, or de-linkage of price from the cost of R&D, but there is a call for new business models as follows:
“actively engage in initiatives and proposals to implement a new business model to bring new antibiotics to the market, including models in which investment costs or revenues are de-linked from sales volumes;”
The European Council conclusions on the next steps under a One Health approach to combat antimicrobial resistance can be viewed here.
Source: Intellectual Property Watch